[1] |
LI Mingying, ZHANG Xiaoxia, SUN Xiaoli, ZHAO Yan, HE Miao, LI Yanling, DUAN Wei, YANG Ou.
Effect of Sugammadex on Recovery of Patients after Laparoscopic Total Pelvic Floor Reconstruction
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(8): 896-901.
|
[2] |
YU Yong, MA Shouliang, SHENG Yuqin.
Allergic Reactions and Treatment Involving Sodium Dimercaptopropane Sulfate Injection during Copper Chelation for Wilson’s Disease
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(7): 771-775.
|
[3] |
YE Ling, LIU Xiaoying, DANG Xuefei, LI Xuelian, LI Gang.
Research Progress in Drugs for Brain Metastases from Advanced Breast Cancer
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(6): 714-720.
|
[4] |
NI Wenqi, ZHU Feng, ZHOU Shuang, CUI Yimin.
Research Progress in Drug-Induced Hypotension
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(4): 475-480.
|
[5] |
CHENG Weineng, PAN Qiuna, YANG Jing, FENG Qiang, TANG Xiaomeng, LIANG Yue.
Retrospective Analysis of 763 Cases of Drug Eruptions
[J]. Chinese Journal of Pharmacovigilance, 2025, 22(1): 104-108.
|
[6] |
ZHANG Jian, ZHANG Lingli, LI Xin.
Immune-related adverse events of tirelizumab in 424 cases of cancer patients
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(4): 435-439.
|
[7] |
JIANG Wenshuo, YANG Li.
Adverse drug reaction among 694 patients in an epilepsy physician-pharmacist joint clinic
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 102-106.
|
[8] |
FAN Xiucong, DONG Xiaohui, CHEN Danxia, BAO Siwei, MA Yabin.
Pharmaceutical care of a patient with Clostridium difficile infection and urinary tract infection during pregnancy
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(5): 579-582.
|
[9] |
LI Meng, LI Rongrong, LIU Chenghai.
Clinic diagnosis and treatment of herb-induced liver injury
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(2): 127-131.
|
[10] |
YUAN Xiaolong, WAN Qihua, TAO Donghong, QI Hao, WANG Aixia.
Pharmaceutical care of a severely poisoned patient with methotrexate tablets
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(8): 924-928.
|
[11] |
ZHU Jinying, ZHOU Sufeng, WANG Lu, XU Mingzhe, SHAO Feng.
Advances in pediatric drug for central sedation based on pharmacokinetic/pharmacodynamic modeling and simulation
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(7): 721-727.
|
[12] |
WEI Xianni, XU Huiyi, HUANG Yuhong, XIE Genying.
Influencing factors and treatment of drug-induced liver injury
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(6): 665-669.
|
[13] |
SU Xinxin, LI Lixun, WANG Zhifei, XIE Yanming, WANG Qi.
Real-world study on Xiyanping injection combined in the treatment of childhood pneumonia
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(1): 47-51.
|
[14] |
MA Yini, ZHANG Lixiang, ZHANG Zhetao, WANG Xiaoyu, SHI Tianlu.
Adverse Drug Reactions of Anti-thyroid Drugs and Effects of 131I Replacement Therapy in Patients with Hyperthyroidism
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(5): 469-472.
|
[15] |
FAN Yan, WANG Dan, WANG Chunting.
The Mechanism of Toxicity Reaction Induced by Protamine Sulfate Injection
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(12): 1159-1161.
|